Hisamitsu Pharmaceutical

Transdermal Patches Global Market Report 2023: Strong Investment in Research and Development Activities by Key Market Players Drives Industry - ResearchAndMarkets.com

Retrieved on: 
星期四, 四月 27, 2023
Health, Other Health, GSK plc, Prevalence, Diabetes, Disease, Cancer, Research, Pain, Incidence, Novartis, Nonsteroidal anti-inflammatory drug, Hisamitsu Pharmaceutical, Conditional sentence, Johnson & Johnson, Chronic pain, Global Burden of Disease Study, Pet industry, Pharmaceutical industry, Poultry farming, Generic drug, Viatris, Dermabrasion

The global market for transdermal patches market was valued at $6.4 billion in 2021.

Key Points: 
  • The global market for transdermal patches market was valued at $6.4 billion in 2021.
  • The market is expected to grow at a compound annual growth rate (CAGR) of 5.6% to reach approximately $8.8 billion by 2027.
  • These factors of the burden of chronic pain are likely to drive the market for transdermal patches during the forecast period.
  • The pain relief patches segment accounted for the highest share of the global market in 2021.

US Transdermal Patch Market USD 6 Billion Opportunity By 2026

Retrieved on: 
星期二, 三月 23, 2021
Health sciences, Routes of administration, Pharmacology, Medicine, Dosage forms, Transdermal patch, Transdermal, Hisamitsu Pharmaceutical

"US Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2026" Report Highlights:

Key Points: 
  • "US Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2026" Report Highlights:
    US Transdermal Patch Clinical Pipeline Insight by Company, Indication & Phase
    Number of Patch In Clinical Trials: > 40 Patch
    Marketed Transdermal Patch Clinical Insight: > 25 FDA Approved Patch
    The US transdermal patch drug market is revolving due to two powerful mega-trends a dynamic acceleration in the total US pharmaceutical market growth and the significant contribution of the researchers for restructuring the entire healthcare sector to a system where the drug delivery mechanisms are modulated in an efficient way.
  • The US transdermal patch drug market is indeed a constructive sector for the entire US pharmaceutical market.
  • US transdermal patch drug market for the benefit of the patient population has been implementing several important strategies that could response to diversifying transdermal patch services in order to address the local need of the patients.
  • As per the extensive research conducted for US Transdermal patch drug market, it is estimated that several single as well as multi-pronged approach initiated by the country's pharmaceutical industry have generated mega-trends responsible for making the entire market sustain numerous phases of growth as well as extensive competitiveness in the global transdermal patch drug market.

US Transdermal Patch Market USD 6 Billion Opportunity By 2026

Retrieved on: 
星期二, 三月 23, 2021
Health sciences, Routes of administration, Pharmacology, Medicine, Dosage forms, Transdermal patch, Transdermal, Hisamitsu Pharmaceutical

"US Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2026" Report Highlights:

Key Points: 
  • "US Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2026" Report Highlights:
    US Transdermal Patch Clinical Pipeline Insight by Company, Indication & Phase
    Number of Patch In Clinical Trials: > 40 Patch
    Marketed Transdermal Patch Clinical Insight: > 25 FDA Approved Patch
    The US transdermal patch drug market is revolving due to two powerful mega-trends a dynamic acceleration in the total US pharmaceutical market growth and the significant contribution of the researchers for restructuring the entire healthcare sector to a system where the drug delivery mechanisms are modulated in an efficient way.
  • The US transdermal patch drug market is indeed a constructive sector for the entire US pharmaceutical market.
  • US transdermal patch drug market for the benefit of the patient population has been implementing several important strategies that could response to diversifying transdermal patch services in order to address the local need of the patients.
  • As per the extensive research conducted for US Transdermal patch drug market, it is estimated that several single as well as multi-pronged approach initiated by the country's pharmaceutical industry have generated mega-trends responsible for making the entire market sustain numerous phases of growth as well as extensive competitiveness in the global transdermal patch drug market.

NAD Finds Salonpas Duration Claim Supported; Recommends Hisamitsu America Discontinue Comparative Pain Relief, Onset of Action, Range of Motion Claims

Retrieved on: 
星期三, 三月 10, 2021
Pain, Nervous system, Branches of biology, Acute pain, Analgesics, Transdermal analgesic patch, Palliative care, Hisamitsu Pharmaceutical

NAD also determined that Hisamitsu provided a reasonable basis for the challenged claims comparing the Salonpas patch's regulatory pathway to competitor products.

Key Points: 
  • NAD also determined that Hisamitsu provided a reasonable basis for the challenged claims comparing the Salonpas patch's regulatory pathway to competitor products.
  • None are proven stronger or more effective against pain than Salonpas Pain Relief Patch Large."
  • Severity of pain claims that characterize the Salonpas patch as the "only pain reliever labeled to relieve mild to tougher, moderate pain" and "the strongest labeled OTC topical pain reliever."
  • improved range of motion" because the study relied on by the advertiser did not investigate changes to range of motion, only pain relief.

Noven Submits New Drug Application for Investigational Dextroamphetamine Transdermal System for ADHD

Retrieved on: 
星期一, 二月 22, 2021
FDA, General Health, Pharmaceutical, Health, Psychoactive drugs, Drugs, Health sciences, Substituted amphetamines, Stimulants, Ergogenic aids, Phenethylamines, Transdermal patch, Hisamitsu Pharmaceutical, Amphetamine, New Drug Application, Food and Drug Administration

Noven Pharmaceuticals, Inc., (Noven) a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today confirmed it has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its dextroamphetamine transdermal system (ATS).

Key Points: 
  • Noven Pharmaceuticals, Inc., (Noven) a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today confirmed it has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its dextroamphetamine transdermal system (ATS).
  • Currently, there is no amphetamine-based transdermal treatment option available for ADHD.
  • The NDA submission is supported by results from a multicenter, laboratory classroom study which evaluated the safety and efficacy of ATS in over 100 pediatric patients with ADHD.
  • Novens mission is to develop and offer pharmaceutical products that meaningfully benefit patients around the world, with a commitment to advancing patient care through transdermal drug delivery.

Global Market for Pain Management Patches

Retrieved on: 
星期一, 六月 22, 2020
Health, Companies, Articles, Analgesics, Transdermal analgesic patch, Hisamitsu Pharmaceutical, Pharmaceutical industry in China, Pfizer, Pharmaceutical industry, Novartis, Pain management, Sanofi

- Analyses of global market trends, with market data from 2017, 2018, and projections of compound annual growth rates (CAGRs) through 2023

Key Points: 
  • - Analyses of global market trends, with market data from 2017, 2018, and projections of compound annual growth rates (CAGRs) through 2023
    - Assessment of current market size, market forecast, and main driving forces for the pain relief patches market
    - Briefing about antihypertensive drugs, their pathophysiology and pathogenesis and major adverse effects of various antihypertensive drugs
    - Information on significant products, issues and trends, market influences, regulatory issues and other information affecting the pain relief patches market
    - Profile description of major market players including Endo Pharmaceuticals Inc., GlaxoSmithKline PLC, Hisamitsu Pharmaceutical Co. Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., and Sanofi
    The global market for pain management patches was valued at $REDACTED billion in 2017.The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED% to reach approximately $REDACTED billion by 2023.
  • The burden of chronic pain is likely to drive the market for pain management patches during the forecast period.
  • The quick implementation of new designs for pain management patcheswhich overcome pain by supplying an adequate dosage of drugs to the surface of bodyby regulatory agencies in recent years is likely to have a profound effect on the market growth of pain management patches.
  • These new pain management patches, with novel mechanisms of action or improved delivery systems, will provide powerful new alternatives for currently prescribed pain management patches.

Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight; 2020 to 2026 - ResearchAndMarkets.com

Retrieved on: 
星期五, 一月 31, 2020
Health, Pharmaceutical, Pharmacology, Health, Dosage forms, Routes of administration, Transdermal patch, Granisetron, Transdermal, Chemotherapy-induced nausea and vomiting, Dermal patch, Hisamitsu Pharmaceutical, Daytrana

The "Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.
  • The report also discusses the ongoing clinical and non-clinical parameters with respect to development of global transdermal patch market and highlights the need for integration of transdermal patches in existing drug delivery methodology available to pharmaceutical companies.
  • Global Transdermal Patch Market Opportunity: > US$ 15 Billion
    Global Transdermal Patch Clinical Pipeline: 100 Patches In Trials
    Global Transdermal Patch Clinical Trials Insight by Company, Drug Class, Indication & Patent Information
    Regional Trends & Market Insight: US, Europe & Asia-Pacific
    Since the advent of the transdermal drug delivery technique, there has been a continuous rise in the market of transdermal patches globally.
  • For instance, granisetron transdermal system is a transdermal patch used to treat chemotherapy-induced nausea and vomiting in a regulated way.

Global Transdermal Patch Industry Outlook and Forecast 2020-2026: Dosage & Price Insights, Clinical Trials by Company, Drug Class, Indication & Patent Information

Retrieved on: 
星期五, 一月 17, 2020
Pharmacology, Health sciences, Health, Routes of administration, Dosage forms, Transdermal patch, Transdermal, Dermal patch, Hisamitsu Pharmaceutical, Daytrana

DUBLIN, Jan. 17, 2020 /PRNewswire/ -- The "Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 17, 2020 /PRNewswire/ -- The "Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.
  • The report also discusses the ongoing clinical and non-clinical parameters with respect to development of global transdermal patch market and highlights the need for integration of transdermal patches in existing drug delivery methodology available to pharmaceutical companies.
  • Global Transdermal Patch Market Opportunity: > US$ 15 Billion
    Global Transdermal Patch Clinical Pipeline: 100 Patches In Trials
    Global Transdermal Patch Clinical Trials Insight by Company, Drug Class, Indication & Patent Information
    Regional Trends & Market Insight: US, Europe & Asia-Pacific
    Since the advent of the transdermal drug delivery technique, there has been a continuous rise in the market of transdermal patches globally.
  • The need of transdermal patch drug delivery has already gained momentum and is sure to play its part in the global pharmaceutical market.

 Noven Announces Appointment of Andrew J. Purcell as Head of Marketing & Sales

Retrieved on: 
星期四, 七月 11, 2019
Health, Pharmaceutical, Companies, Health, Articles, Hisamitsu Pharmaceutical, Bristol-Myers Squibb, AstraZeneca, Vice president, Purcell, Pharmaceutical industry in China, Transdermal patch, HP-3070, Schizophrenia, Noven Pharmaceuticals, Inc.

Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Japan-based Hisamitsu Pharmaceutical Co., Inc., announced the appointment of Andrew J. Purcell as Novens Head of Marketing & Sales.

Key Points: 
  • Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Japan-based Hisamitsu Pharmaceutical Co., Inc., announced the appointment of Andrew J. Purcell as Novens Head of Marketing & Sales.
  • View the full release here: https://www.businesswire.com/news/home/20190711005443/en/
    Noven announces appointment of Andrew J. Purcell, Head of Marketing and Sales (Photo: Business Wire)
    In this new role, Mr. Purcell will develop and lead Novens marketing and sales team as Noven prepares for the potential launch and commercialization of HP-3070 (asenapine) transdermal drug delivery system (TDDS), a new investigational patch product for the treatment of schizophrenia.
  • Vice President, Global Commercialization for BYDUREON at AstraZeneca/Bristol-Myers Squibb, with responsibility for leading the development of commercial strategies for new products.
  • Positions of increasing responsibility at Novo Nordisk, including Vice President, Strategic Business Development and Vice President, Diabetes Marketing.